← Leaderboards
Jonathan A Winger
Omniox, Inc.
$3,362,152
Attributed
$7,749,863
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,749,863 · 3
By mechanism
R44$6,141,690 · 2
R01$1,608,173 · 1
Top collaborators
- Emin Maltepe6 shared
- Jeffrey R Fineman5 shared
- Ana Krtolica4 shared
- Simon R Cherry2 shared
- Michael Sean Kent2 shared
- Allison Zwingenberger2 shared
- Natacha Le Moan1 shared
Most similar at Omniox, Inc.
Same institution · by research overlap
- Ana Krtolica$1,680,034
- Natacha Le Moan$901,737
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesDesignSmall Business Innovation Research GrantSafetyProteinsOxygenLeadUniversitiesPreclinical StudyExposure ToMedicalCarrier ProteinsHypoxiaTreatment EfficacyCaliforniaClinically RelevantSan FranciscoTranslational ApproachPathologyPreventBiochemicalBlood VesselsClinical TrialsAward
Grant awards (11)
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$991,379
R44 · FY2025 · HD · contact PI
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$995,592
R44 · FY2024 · HD · contact PI
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$999,580
R44 · FY2023 · HD · contact PI
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$522,676
R01 · FY2022 · CA · contact PI
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$538,027
R01 · FY2021 · CA · contact PI
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$232,127
R44 · FY2020 · HD · contact PI
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$704
R01 · FY2020 · CA
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$681,601
R44 · FY2019 · HD
Development of PET imaging biomarkers to predict enhanced glioblastoma radiotherapy by a novel H-NOX oxygen carrier$546,766
R01 · FY2019 · CA
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$1,032,262
R44 · FY2018 · HD
Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier$1,209,149
R44 · FY2017 · NS